Magenta Therapeutics
100 Technology Square, 5th Floor
Cambridge
Massachusetts
02139
United States
Website: https://www.magentatx.com/
Email: careers@magentatx.com
About Magenta Therapeutics
Magenta Therapeutics is a clinical-stage biotechnology company developing therapeutics to reset the immune system to cure more patients with devastating and life-threatening diseases. This immune reset approach can be applied through stem cell transplant to multiple diseases, including autoimmune diseases, such as multiple sclerosis and systemic sclerosis; blood cancers, such as acute myeloid leukemia; and genetic diseases, such as sickle cell disease.
Magenta's comprehensive approach to precision immune system reset will transform many aspects of the transplant process, aiming to make it safer and more effective. Our culture is fueled by a driven, passionate group of people committed making a difference, seizing opportunities to make maximum impact and pursuing progress for the patients we seek to serve.
Stock Exchange: NASDAQ
Stock Symbol: MGTA
158 articles about Magenta Therapeutics
-
Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement
5/3/2023
Magenta Therapeutics, Inc. (Nasdaq: MGTA) (“Magenta”) and Dianthus Therapeutics, Inc. (“Dianthus”), a privately-held, clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, announced today that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.
-
Magenta Therapeutics Adopts Limited Duration Stockholder Rights Plan
3/31/2023
Magenta Therapeutics, Inc. announced that its Board of Directors has unanimously adopted a limited duration stockholder rights plan.
-
Magenta Therapeutics is cutting about 84% of its workforce after a patient's death halted a Phase I/II trial in acute myeloid leukemia.
-
Magenta Therapeutics to Explore Strategic Alternatives
2/2/2023
Magenta Therapeutics, a clinical-stage biotechnology company focused on improving stem cell transplantation, announced that it has completed a review of its business, including the status of its programs, resources, and capabilities.
-
Patient Death Pauses Another AML Trial
1/26/2023
Following the death of a patient, Magenta Therapeutics placed a hold on Phase I/II dose-escalation trial of its acute myeloid leukemia therapy. -
Magenta Therapeutics Voluntarily Pauses the MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial to Investigate Drug Safety
1/25/2023
Magenta Therapeutics (Nasdaq: MGTA) today announced that the latest participant dosed at the Cohort 3 level (0.08 mg/kg) in the ongoing MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) experienced a Grade 5 Serious Adverse Event (SAE) (respiratory failure and cardiac arrest resulting in death) deemed to be possibly related to MGTA-117.
-
Magenta Therapeutics Provides Update for MGTA-117 Phase 1/2 Dose Escalation Clinical Trial
12/20/2022
Magenta Therapeutics (Nasdaq: MGTA) today announces that, per the clinical trial protocol for the MGTA-117 Phase 1/2 Dose Escalation Clinical Trial in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), it has stopped dosing participants at the Cohort 4 dosing level (0.13 mg/kg) and plans to dose additional participants at the Cohort 3 dosing level (0.08 mg/kg).
-
Magenta Therapeutics to Host Conference Call and Webcast on Tuesday, December 13, 2022, to Review MGTA-117 Clinical Data from Ongoing Phase 1/2 Clinical Trial
12/12/2022
Magenta Therapeutics, a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, announced that it will host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m.
-
Magenta Therapeutics Presents Positive MGTA-117 Clinical Data at the American Society of Hematology (ASH) Annual Meeting and Provides Program Updates
12/12/2022
Magenta Therapeutics (Nasdaq: MGTA) highlights updated clinical data from the ongoing MGTA-117 Phase 1/2 dose-escalation clinical trial made in an oral presentation today at the American Society of Hematology 2022 Annual (ASH) Meeting in New Orleans and provides program updates across the portfolio.
-
Magenta Therapeutics to Present Data at the 2022 American Society of Hematology (ASH) Annual Meeting
11/3/2022
Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today announced that it will make three presentations relating to its ongoing clinical trials at the 2022 American Society of Hematology (ASH) Annual Meeting.
-
Magenta Therapeutics Reports Third Quarter 2022 Financial Results and Recent Program Highlights
11/3/2022
Magenta Therapeutics reported financial results for the third quarter ending September 30, 2022, and recent program highlights.
-
Magenta Therapeutics to Participate in the Credit Suisse 31st Annual Healthcare Conference
11/1/2022
Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today announced that the company will present at the Credit Suisse 31st Annual Healthcare Conference being held November 7-10, 2022.
-
Magenta Therapeutics Appoints Michael Vasconcelles, M.D. to the Board of Directors
8/17/2022
Magenta Therapeutics today announced that it has appointed Michael Vasconcelles, M.D. to its board of directors.
-
Magenta Therapeutics Reports Second Quarter 2022 Financial Results and Recent Program Highlights
8/4/2022
Magenta Therapeutics, a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, reported financial results for the second quarter ending June 30, 2022, and recent program highlights.
-
Magenta Therapeutics to Participate in Panel Discussion at the 2022 Wedbush PacGrow Healthcare Conference
8/2/2022
Magenta Therapeutics today announced that the company will participate in a Gene Modulation Panel Discussion at the 2022 Wedbush PacGrow Healthcare Conference, to be held virtually, on Tuesday, August 9th, 2022 at 9:45 a.m. ET.
-
Magenta Therapeutics Reports First Quarter Financial Results, Early Clinical Observations from MGTA-117 Clinical Trial and Other Program Highlights
5/16/2022
Magenta Therapeutics Reports First Quarter Financial Results, Early Clinical Observations from MGTA-117 Clinical Trial and Other Program Highlights.
-
Magenta Therapeutics Focuses R&D and Operational Spending, Reduces Workforce and Extends Cash Runway
4/14/2022
Magenta Therapeutics Focuses R&D and Operational Spending, Reduces Workforce and Extends Cash Runway.
-
The revised operating plan also includes reductions in spending related to general and administrative expenses and investments in its research platform.
-
Magenta Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Program Highlights
3/8/2022
Magenta Therapeutics today reported financial results for the fourth quarter and full-year ended December 31, 2021, and recent program highlights.
-
Magenta Therapeutics to Participate in Panel Discussion at the 42nd Annual Cowen Healthcare Conference
3/3/2022
Magenta Therapeutics to Participate in Panel Discussion at the 42nd Annual Cowen Healthcare Conference.